Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24113103 | 1.00 | CTSL (0.42) | CTSL | |
| SCHEMBL24020461 | 1.00 | CTSL (0.42) | CTSL | |
| SCHEMBL25835207 | 1.00 | CTSL (0.42) | CTSL | |
| Ammonia Solution, Strong SCHEMBL26119246 | 0.99 | CTSL (0.41) | CTSL | |
| SCHEMBL25134723 | 0.93 | CTSS (0.40) | — | |
| SCHEMBL24754818 | 0.93 | CTSS (0.40) | — | |
| SCHEMBL24113318 | 0.93 | CTSS (0.40) | — | |
| SCHEMBL24425123 | 0.92 | — | — | |
| SCHEMBL28732881 | 0.92 | — | — | |
| SCHEMBL24690562 | 0.91 | CTSL (0.51) | CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | TRAWSFYNYDD THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4635972-A2 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4051265-B1 | FUNCTIONALIZED PEPTIDES CONTAINING TWO PYRROLIDINE RINGS AS ANTICORONAVIRUS AGENTS | ENANTA PHARM INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-4551569-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4540227-A2 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | Trawsfynydd Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250074938-A1 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-03-06 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220048944-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220041652-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220033383-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021226546-A1 | PROTEASE INHIBITORS FOR TREATMENT OR PREVENTION OF CORONAVIRUS DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074938-A1 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | ACE, TMPRSS2, ACE2 | CTSL 24/4885 |
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | ACE2, ACE, TMPRSS2 | CTSL 20/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CTSL 3/4885 |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | CTSL 3/4885 |
| US-20220041652-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | CTSL 331/4885 |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885 |
| US-20220048944-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | CTSL 331/4885 |
| US-20220073499-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | CTSL 331/4885 |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSL 3/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CTSL 1088/4885 |
| US-20220033383-A1 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | SARS1, VIP, ACE | CTSL 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.